After a series of duplication and rearrangement events, the genes involved in two key pathways producing morphine, codeine, and noscapine have clustered in the genome.
The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.
The team said that by understanding why some members of this family don't feel pain, they could unearth new drug targets to treat others with chronic pain.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The one-year partnership will focus on identifying patients with abnormal pain conditions and validating the genetic findings as potential targets for drugs.
Smaller labs, hospital outreach labs, and labs servicing high numbers of elderly are thought to face the highest risks.
The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.
The firm has yet to publish peer-reviewed clinical evaluations, and genetics experts have raised doubts about its choice of targets to predict addiction.
The companies plan to combine their platforms and research to launch new clinical assays and develop procedures and therapeutics to treat pain.
In Nature this week: short tandem repeats contribute to gene expression variation in humans, mutation linked to cold-aggravated peripheral pain, and more.
The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.
The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.
Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.
In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.